TLUS was significantly shorter in the RIF-MMX group ( median : 46.0 hours ) compared with placebo ( median : 68.0 hours ; p = 0.0008 ) and a larger percentage of RIF-MMX treated patients ( 81.4 % ) achieved clinical cure compared with placebo patients ( 56.9 % ) .